Moderate Psoriatic Arthritis: Achieving Treatment Targets With Apremilast
Hier geht's zu aktuellen Abstracts vom EULAR im Juni 2019 in Madrid
(siehe "PDF Download" rechts oben)
1 Probability of Achieving Low Disease Activity or Remission in Subjects With Active Psoriatic Arthritis Treated With Apremilast
Mease PJ, et al. Ann Rheum Dis. 2019;78(suppl2):FRI0450.
2 Achievement of cDAPSA Low Disease Activity or Remission Is Associated With Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated With Apremilast
Coates LC, et al. Ann Rheum Dis. 2019;78(suppl2):AB0741.
3 Impact of Apremilast on PsAID Core Components in Patients With a Limited Number of Active Joints: Results From the Real-World, Prospective, Multicentre REWARD Study
Jansen TJ, et al. Ann Rheum Dis. 2019;78(suppl2):FRI0443.
✉ Neues zu Psoriasis-Arthritis?